ACADVL Sequence Analysis (Familial Mutation/Variant Analysis)

Clinical Use

Use

The ACADVL Sequence Analysis is specifically designed for analyzing known familial variants in the context of very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency. This metabolic disorder is inherited in an autosomal recessive manner, leading to a failure to break down long-chain fats, thus presenting symptoms that can range from hypertrophic cardiomyopathy in infants to muscle cramps in adults. Early detection and intervention are crucial, allowing for normal physical and mental development when managed properly. Testing is appropriate for symptomatic patients or for those planning pregnancies, provided there is a known familial variant. Reports must include relevant familial variant information and patient relationships to ensure proper clinical interpretation.

Special Instructions

A laboratory report detailing the relative's variant information, the biological relationship of the tested individual, and their clinical status must accompany the specimen. Discussions with a genetic counselor are required if the familial variant was identified in another laboratory before specimen submission. Test ordering, specimen collection coordination, and considerations for familial variants are vital components of the process for accurate results.

Limitations

The ACADVL Sequence Analysis relies heavily on the existence of a previously identified familial variant. Thus, patients without known variants or without proper documentation cannot be tested. Variants must be confirmed in the family tree to utilize this analysis effectively. This test cannot determine new mutations outside the specified familial context, which limits its application to specific families. Additionally, if specimens are not collected and shipped under the recommended conditions, results may be compromised, leading to potential delays or inaccurate findings.

Test Details